MENU
GLSI
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Greenwich LifeSciences (GLSI) Ownership - Who owns Greenwich LifeSciences?
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences... Show more
Profile
Industry
N/A
Address
3992 Bluebonnet Drive
Phone
+1 832 819-3232
Employees
6
Web
https://www.greenwichlifesciences.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
132.6M
P/E Ratio
N/A
Total Cash
5.82M
Projected Growth
N/A
Total Debt
N/A
Revenue
N/A
Risk (Beta)
2.02
Dividend Yield
N/A
Total Cash/Share
0.44
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
GLSI
Capitalization
133M
P/E Ratio
N/A
Risk (Beta)
2.02
Dividend Yield
N/A
Total Cash
5.82M
Total Cash/Share
0.44
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
4.98M
P/B Ratio
51.55
Cash Flow
N/A
Earnings
-0.81
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
13.1K
Current Ratio
6.91
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-10.76M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-140.17
Shares Held By Institutions
22.8M
Shares Outstanding - Current
13.3M
Total Liabilities
842K
Total Volume MTD
N/A
Value
-1
Gain YTD
-12.199
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
3992 Bluebonnet Drive
Phone
+1 832 819-3232
Employees
6
Web
https://www.greenwichlifesciences.com